Kamada Ltd.
KMDAKamada Ltd. in brief
Kamada Ltd. is a listed company in the Pharmaceutical industry, based in Israel. It was founded in 1990. Its market value was $463 M on 1 August 2026, which makes it the 12,881st largest listed company in the world and the 142nd largest in Israel on this site. In the year to December 2025 it had sales of $180 M and a net profit of $20 M, about 11 cents of profit for every dollar of sales. It employs about 393 people and Amir London is its chief executive. Its largest product and service lines by sales in 2025 were Proprietary Products (87%) and Distribution (13%). By market, the largest shares of its 2025 sales came from U.S.A (55%), Israel (16%) and Latin America (13%). Its shares trade under the symbol KMDA (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Kamada Ltd.
Under the Israeli Economic Competition Law, 5758-1988, as amended, a company that supplies or acquires more than 50% of any product or service in Israel in a relevant market may be deemed to be a monopoly. In addition, any company that has “significant market power” (within the meaning of the Competition Law), even if it does not hold market share that is greater than 50%, shall be deemed to be a monopolist under the Competition Law. A monopolist is prohibited from participating in certain business practices, including unreasonably refusing to sell products or provide services over which a monopoly exists, charging unfair prices for such products or services, and abusing its position in the market in a manner that might reduce business competition or harm the public. In addition, the General Director of the Israeli Competition Authority may determine that a company is a monopoly and has the right to order such company to change its conduct in matters that may adversely affect business competition or the public, including by imposing restrictions on its conduct. Depending on the analysis and the definition of the different products we distribute in the markets in which we operate, we may be deemed to be a “monopoly” under the Competition Law with respect to certain of our products. Furthermore, following an amendment to the Competition Law that became effective in August 2015, which repealed the statutory exemption that existed under the Competition Law for restrictive arrangements that were mutually exclusive arrangements, we may face difficulties in certain cases negotiating distribution agreements with foreign pharmaceutical manufacturers.
From the company's annual report filed with the US SEC: read the report
Kamada Ltd. timeline
- 1990
- 🏁· approximateFounded
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 31 May 2013; shares registered for exchange trading on 28 May 2013.
Events of Kamada Ltd. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #128 (Jan 2020) · #135 (Jan 2021) · #201 (Jan 2022) · #194 (Dec 2022) · #180 (Jul 2023) · #164 (Jan 2024) · #20 (Mar 2026) · #143 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- 22.9×
- Price / sales (TTM)
- 2.6×
- Price / book
- 1.7×
- Free cash flow yield
- 3.4%
- Net margin (TTM)
- 11.2%
- Operating margin
- 14.5%
- Return on equity
- 7.5%
- Liabilities / assets
- 29.0%
- Net debt
- $-17M
- Revenue growth
- +12.1%
- R&D / revenue
- 7.2%
- Revenue per employee
- $459 K
- Profit per employee
- $51 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $180M | +12.1% | $26M | $20M | 11.2% |
| Dec 2024 | $161M | +12.9% | $20M | $14M | 9.0% |
| Dec 2023 | $143M | +10.2% | $10M | $8M | 5.8% |
| Dec 2022 | $129M | +24.8% | $5M | $-2M | -1.8% |
| Dec 2021 | $104M | -22.2% | $-1M | $-2M | -2.2% |
| Dec 2020 | $133M | +4.8% | $19M | $17M | 12.9% |
| Dec 2019 | $127M | +11.1% | $23M | $22M | 17.5% |
| Dec 2018 | $114M | — | $19M | $22M | 19.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $25M | $10M | $16M | $0.35 | — |
| Dec 2024 | $48M | $11M | $37M | $0.25 | — |
| Dec 2023 | $4M | $6M | $-2M | $0.15 | — |
| Dec 2022 | $29M | $4M | $25M | $-0.05 | — |
| Dec 2021 | $-9M | $4M | $-13M | $-0.05 | — |
| Dec 2020 | $19M | $5M | $14M | $0.38 | — |
| Dec 2019 | $28M | $2M | $25M | $0.55 | — |
| Dec 2018 | $11M | $3M | $8M | $0.55 | — |
SEC filings
- Nov 19, 20266-KReport of foreign issuer
- Nov 9, 20266-KReport of foreign issuer
- Nov 2, 20266-KReport of foreign issuer
- Oct 6, 20266-KReport of foreign issuer
- Oct 5, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Sep 10, 20266-KReport of foreign issuer
- Sep 3, 20266-KReport of foreign issuer
- Aug 17, 20266-KReport of foreign issuer
- Aug 12, 20266-KReport of foreign issuer
- Aug 5, 20266-KReport of foreign issuer
- Aug 5, 20266-KReport of foreign issuer
Official filings of Kamada Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $180 M
- Operating income
- $26 M
- Net income
- $20 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $379 M
- Total liabilities
- $110 M
- Total equity
- $269 M
As of December-2025
Top 60 institutional investors in Kamada Ltd.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Phoenix Financial Ltd. | 1,649,734 | -5,218 (-0.32%) | $14 M | Nov 9, 2026 |
| 2 | Renaissance Technologies LLC | 819,605 | +77,187 (+10.40%) | $7 M | Nov 12, 2026 |
| 3 | Wells Fargo & Company/mn | 595,563 | +3,499 (+0.59%) | $5 M | Nov 16, 2026 |
| 4 | Arrowstreet Capital, Limited Partnership | 571,249 | New | $5 M | Nov 13, 2026 |
| 5 | Acadian Asset Management LLC | 450,593 | +296,218 (+191.88%) | $4 M | Nov 9, 2026 |
| 6 | Goldman Sachs Group Inc | 399,299 | +340,253 (+576.25%) | $3 M | Nov 16, 2026 |
| 7 | Dimensional Fund Advisors LP | 330,405 | +28,725 (+9.52%) | $3 M | Nov 4, 2026 |
| 8 | Two Sigma Investments, LP | 277,313 | +126,213 (+83.53%) | $2 M | Nov 16, 2026 |
| 9 | Bank Of America Corp /de/ | 204,881 | New | $2 M | Nov 16, 2026 |
| 10 | Marshall Wace, LLP | 188,037 | +112,855 (+150.11%) | $2 M | Nov 13, 2026 |
| 11 | Huntleigh Advisors, Inc. | 168,072 | +5,428 (+3.34%) | $1 M | Nov 3, 2026 |
| 12 | Renaissance Group LLC | 150,164 | +25,268 (+20.23%) | $1 M | Nov 12, 2026 |
| 13 | Envestnet Asset Management Inc | 122,048 | +67,379 (+123.25%) | $1 M | Nov 16, 2026 |
| 14 | Jane Street Group, LLC | 102,845 | +81,537 (+382.66%) | $1 M | Nov 12, 2026 |
| 15 | Millennium Management LLC | 97,562 | +68,356 (+234.05%) | $1 M | Nov 16, 2026 |
| 16 | Quadrature Capital Ltd | 78,654 | +44,404 (+129.65%) | $1 M | Nov 13, 2026 |
| 17 | UBS Group AG | 70,420 | +64,845 (+1163.14%) | $1 M | Nov 10, 2026 |
| 18 | Stifel Financial Corp | 68,524 | +30,125 (+78.45%) | $1 M | Nov 12, 2026 |
| 19 | Man Group plc | 65,703 | +3,814 (+6.16%) | $1 M | Nov 16, 2026 |
| 20 | BlackRock, Inc. | 49,050 | +3,676 (+8.10%) | $0 M | Nov 13, 2026 |
| 21 | LSV Asset Management | 47,800 | 0 (0.00%) | $0 M | Nov 6, 2026 |
| 22 | Aristides Capital LLC | 44,359 | +8,328 (+23.11%) | $0 M | Nov 16, 2026 |
| 23 | Barclays PLC | 43,882 | +32,495 (+285.37%) | $0 M | Nov 6, 2026 |
| 24 | XTX Topco Ltd | 34,765 | +3,415 (+10.89%) | $0 M | Nov 16, 2026 |
| 25 | Geode Capital Management, LLC | 33,113 | -4,390 (-11.71%) | $0 M | Nov 6, 2026 |
All 60 institutional investors: 26 to 60, with who bought and sold →
Mutual funds holding Kamada Ltd.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP | 203,071 | $1 M | 0.32% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 98,548 | $1 M | 0.15% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap Value ETFDimensional Fund Advisors LP | 60,576 | $0 M | 0.09% | <0.01% | +26% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 53,547 | $0 M | 0.08% | <0.01% | +41% | Jul 31, 2026 |
| 🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP | 45,903 | $0 M | 0.07% | <0.01% | +70% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 37,503 | $0 M | 0.06% | <0.01% | +28% | May 31, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 28,075 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 20,160 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Siit World Equity Ex-Us FundSEI INVESTMENTS MANAGEMENT CORPORATION | 12,431 | $0 M | 0.02% | <0.01% | −23% | May 31, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 9,872 | $0 M | 0.02% | <0.01% | +35% | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 8,915 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP | 8,369 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP | 7,363 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP | 6,066 | $0 M | <0.01% | <0.01% | +29% | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 5,054 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors | 4,670 | $0 M | <0.01% | <0.01% | +2.1% | Jul 31, 2026 |
| 🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 4,386 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust | 3,649 | $0 M | <0.01% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 3,545 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 1,616 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP | 1,450 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 700 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 634 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis International Equity ETFAmerican Century ETF Trust | 543 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Avantis International Equity FundAmerican Century ETF Trust | 160 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
As of Jul 31, 2026
Insider trading at Kamada Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Yael BrennerVP Quality | Option exercise | +5,000 | 5.930 | 30 Klocal | 11,266 | Form 4 |
| filed | Nir LivnehVP, General Counsel | Option exercise | +10,000 | 5.370 | 54 Klocal | 10,000 | Form 4 |
| filed | David TsurDirector | Sell | -22,827 | 8.180 | 187 Klocal | 407,929 | Form 4 |
| filed | Yael BrennerVP Quality | Shares withheld for tax | -1,371 | 8.360 | 11 Klocal | 6,266 | Form 4 |
| filed | Nir LivnehVP, General Counsel | Shares withheld for tax | -3,459 | 8.350 | 29 Klocal | 0 | Form 4 |
| filed | Yael BrennerVP Quality | Option exercise | +5,000 | 5.930 | 30 Klocal | 11,266 | Form 4 |
| filed | Yael BrennerVP Quality | Shares withheld for tax | -1,371 | 8.360 | 11 Klocal | 6,266 | Form 4 |
| filed | Yael BrennerVP Quality | Option exercise | +5,000 | 5.930 | 30 Klocal | 11,266 | Form 4 |
Markets and events: Kamada Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-12-08 11:55 UTC, code T3, resumed 12:20 UTC
Fails to deliver
- : 4,458 shares at $8.26
- : 4,655 shares at $7.58
- : 66 shares at $7.09
- : 29 shares at $7.05
- : 3 shares at $7.27
Kamada Ltd. scorecard#
Passes 10 of the 12 checks that could be worked out: strongest in growth (6 of 6), weakest in profitability (3 of 5). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
Growth6 of 6
Profitability3 of 5
Financial health1 of 1
Shareholder returnsnot known
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Kamada Ltd.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 14.5% | 1.4% | |
| Net margin | 11.2% | -1.9% | |
| Return on equity | 7.6% | -1.5% | |
| Revenue growth, 3 years a year | 11.7% | 2.5% | |
| Revenue growth | 12.1% | 7.3% | |
| Free cash flow margin | 8.7% | 5.8% |
5of 7on the Piotroski tests of financial strength
- Revenue has grown 4 years in a row.
Kamada Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 180 | 161 | 143 | 129 | 104 | 133 | 127 | 114 | 103 | 77 | |
| Cost of revenue | 104 | 91 | 87 | 83 | 73 | 86 | 77 | 73 | 71 | 56 | |
| Gross profit | 76 | 70 | 55 | 47 | 30 | 48 | 50 | 41 | 32 | 21 | |
| Research and development | 13 | 15 | 14 | 13 | 11 | 14 | 13 | 9.7 | 12 | 16 | |
| Selling, general and administrative | — | — | — | 1.8 | 0.3 | — | — | — | — | — | |
| Selling and marketing | 18 | 18 | 16 | 15 | 0.9 | 4.5r | 4.4 | 3.6r | 0.6 | 0.5 | |
| General and administrative | — | — | — | — | — | 10 | 9.2 | 8.5 | — | — | |
| Total costs and expenses | — | — | — | — | — | 0.1 | 0.0 | — | — | — | |
| Operating income | 26 | 20 | 10 | 4.5 | −0.7 | 19 | 23 | 19 | 7.4 | −5.5 | |
| Interest and finance income | 1.9 | 2.1 | 0.6 | 0.1 | 0.3 | 1.0 | 1.1 | 0.8r | 0.5 | 0.5 | |
| Interest expense and finance costs | 0.9 | 0.7 | 1.3 | 0.9 | 0.3r | 0.3 | 0.3 | 0.2r | 0.1r | 0.1 | |
| Income before tax | 23 | 13 | 8.4 | −2.3 | −1.9 | 19 | 23 | 20 | 7.2 | −5.0 | |
| Income tax | 3.3 | −1.1 | 0.1 | 0.1 | 0.3 | 1.4 | 0.7 | −2.0 | 0.3 | 1.7 | |
| Net income including minority interests | 20 | 14 | 8.3 | −2.3 | −2.2 | 17 | 22 | 22 | 6.9 | −6.7 | |
| Net income attributable to shareholders | — | 14 | 8.3 | −2.3 | — | — | — | — | — | — | |
| Earnings per share, basic | 0.35 | 0.25 | 0.17 | -0.05 | -0.05 | 0.39 | 0.55 | 0.55 | 0.18 | -0.18 | |
| Earnings per share, diluted | 0.35 | 0.25 | 0.15 | -0.05 | -0.05 | 0.38 | 0.55 | 0.55 | 0.18 | -0.18 | |
| Shares, weighted average (basic) | 58 | 57 | 49 | 45 | 45 | 44 | 40 | 40 | 38 | 36 | |
| Shares, weighted average (diluted) | 58 | 58 | 54 | 45 | 45 | 45 | 41 | 40 | 38 | 36 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 75 | 78 | 56 | 34 | 19 | 70 | 43 | 18 | 13 | 10.0 | |
| Short-term investments | — | — | — | — | — | 39 | 31 | — | — | — | |
| Receivables | 27 | 22 | 20 | 27 | 35 | 22 | 23 | 28 | 31 | 20 | |
| Inventory | 85 | 79 | 88 | 69 | 67 | 42 | 43 | 29 | 21 | 26 | |
| Other current assets | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.2 | — | — | — | — | |
| Current assets | 193 | 184 | 170 | 139 | 130 | 178 | 144 | 111 | 97 | 77 | |
| Property, plant and equipment | 41 | 36 | 28 | 26 | 26 | 26 | 25 | 25 | 25 | 23 | |
| Right-of-use (leased) assets | 8.9 | 9.6 | 7.8 | 2.6 | 3.1 | 3.4 | 4.0 | 4.2 | — | — | |
| Goodwill | 30 | 30 | 30r | 147 | — | — | — | — | — | — | |
| Other intangible assets | — | — | — | — | 154 | 1.5 | — | — | — | — | |
| Non-current assets | 186 | 188 | 185 | 183 | 189 | 33 | 30 | 27 | 25 | 23 | |
| Total assets | 379 | 372 | 355 | 322 | 319 | 211 | 174 | 138 | 122 | 100 | |
| Accounts payable | 23 | 28 | 25r | 7.6 | 7.1 | 7.5r | 25 | 17 | 18 | 16 | |
| Debt due within a year | — | — | — | 4.4 | 2.6 | 0.2 | 0.5 | 0.5r | 0.6 | 0.4 | |
| Current liabilities | 47 | 49 | 50 | 76 | 54 | 0.2 | 33 | 24 | 29 | 27 | |
| Long-term debt | — | — | — | 17 | 20 | 0.3 | 0.7 | 0.7r | 2.0 | 1.8 | |
| Lease liabilities (non-current) | 9.4 | 9.4 | 7.4 | — | — | — | — | — | — | — | |
| Non-current liabilities | 62 | 63 | 61 | 71 | 88 | 7.1 | 5.7 | 2.2 | 3.2 | 5.7 | |
| Retained earnings | −17 | −26 | −40 | −48 | −46 | −44 | −61 | −83 | −105 | −111 | |
| Total equity | 269 | 259 | 244 | 176 | 177 | 179 | 135 | 112 | 89 | 67 | |
| Total liabilities and equity | 379 | 372 | 355 | 322 | 319 | 211 | 174 | 138 | 122 | 100 | |
| Shares outstanding | 58 | 58 | 57 | 45 | 45 | 45 | 40 | 40 | 40 | 36 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 15 | 14 | 13 | 12 | 5.6 | 4.9 | 4.5 | 3.7 | 3.5 | 3.5 | |
| Share-based compensation | 0.8 | 0.9 | 1.3 | 1.2 | 0.5 | 1.0 | 1.2 | 0.9 | 0.5 | 1.1 | |
| Cash from operating activities | 25 | 48 | 4.3 | 29 | −8.8 | 19 | 28 | 11 | 3.6 | 1.9 | |
| Capital expenditure | −9.8 | −11 | −5.9 | −3.8 | −3.7 | −5.5 | −2.3 | −2.9 | −4.2 | −2.6 | |
| Intangible assets bought | — | — | — | — | −0.5 | — | — | — | — | — | |
| Cash from investing activities | −9.8 | −11 | −5.8 | −3.8 | −61 | −13 | −0.6 | −5.2 | −16 | 1.6 | |
| Debt issued | — | — | — | — | 20 | — | — | — | 0.3 | 1.7 | |
| Debt repaid | — | — | −17 | −2.6 | −0.2 | −0.5 | −0.5 | −0.5r | −0.4r | −0.2 | |
| Dividends paid | −12 | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | −18 | −14 | 23 | −9.3 | 19 | 23 | −1.5 | −0.6 | 15 | 1.5 | |
| Exchange-rate effect on cash | −0.3 | −0.2 | 0.2 | 0.2 | −0.3 | −1.8 | −0.9 | 0.6 | −0.6 | −0.1 | |
| Change in cash | −3.0 | 23 | 21 | 16 | −52 | 28 | 25 | 5.4 | 2.7 | 4.9 | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Dec 31, 2025
What Kamada Ltd. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Proprietary Products$156 M87%+10%
- Distribution$24 M13%+24%
As of Dec 31, 2025
Where Kamada Ltd. operates: 4 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇱 Israel | Headquarters1 office1 subsidiary | $30 M16% |
| 🇺🇸 USA | 2 subsidiaries | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
| 🇨🇦 Canada | $11 M6.0% |
How Kamada Ltd. compares in Pharmaceutical
- Market cap$463 M · higher than 34% of 395
- Revenue$180 M · higher than 30% of 329
- Net margin11.2% · higher than 61% of 315
- Revenue growth12.1% · higher than 65% of 112
- P/E ratio22.9× · lower than 51% of 174
- Price / sales2.6× · lower than 47% of 220
- Price / book1.7× · lower than 61% of 208
- FCF yield3.4% · higher than 51% of 71
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kamada Ltd.🇮🇱 | $463 M | 22.9× | 11.2% | +12.1% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
How current the figures are
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kamada Ltd.? Verify and update this profile — free
Show Kamada Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.